Effect of MD1003 in Spinal Progressive Multiple Sclerosis (MS-SPI)
Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study
Sponsor: MedDay Pharmaceuticals SA
This PHASE3 trial investigates Multiple Sclerosis and is currently ongoing. MedDay Pharmaceuticals SA leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Apr 2019 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Jan 2017 — Apr 2017 [monthly]
Unknown Status PHASE3
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MedDay Pharmaceuticals SA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bordeaux, France , Caen, France , Clermont-Ferrand, France , Dijon, France , Lyon, France , Marseille, France , Montpellier, France , Nancy, France , Nantes, France , Nice, France and 6 more locations